The market is currently not exactly stable due to a range of factors and investors are often on the lookout for stocks that have managed to buck the trend somewhat. There are some stocks that have managed to buck the trend quite spectacularly and one of those is the Therapeutic Solutions International (OTCMKTS:TSOI) stock.
The stock continued on its upward move on Thursday and ended up with gains of as much as 20%. That took the cumulative gains made by the stock over the course of the past week to as much as 48%. In light of such considerable gains, it may be a good time for investors to consider having a closer look at the recent developments.
The company announced that its universal donor cell product had therapeutic effects which could be mediated, in part, by CD103, which expresses dendritic cells. The company performed a series of experiments and discovered that the protection from Acute Respiratory Distress Syndrome (ARDS) and Chronic Obstructive Pulmonary Disease (COPD) may be transferred to dendritic cells that express CD103, a molecule. The announcement was made by the company earlier this week back on October 3 and it goes without saying that it was a major new development for Therapeutic Solutions International.
At this point in time, the company is involved in the running of a Phase III clinical trial with regard to the use of JadiCells for treating COVID-18 which could be related to ARDS. On the other hand, the company has also been exploring the possibility of a New Drug Application for treating COPD. At this point in time, Therapeutic Solutions International is still in discussions with the United States Food and Drug Administration with regard to the New Drug Application. It remains to be seen if the stock can manage to add to its gains today.